Nonhematologic complications of erythropoietin therapy

Seminars in Dialysis

Volumn 19, Issue 4, 2006, Pages 279-284

  Zhu, Xiaolei ^a   Perazella, Mark A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33746255946     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Evans RW, Manninen DL, Garrison LP Jr, Hart LG, Blagg CR, Gutman RA, Hull AR, Lowrie EG: The quality of life of patients with end-stage renal disease. N Engl J Med 312:553-559, 1985
2. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, Benz RL: Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25:548-554, 1995
3. Macdougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies ME, Hutton RD, Fox KA, Coles GA, Williams JD: Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 335:489-493, 1990
4. Silberberg J, Racine N, Barre P, Sniderman AD: Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 6:1-4, 1990
5. Marsh JT, Brown WS, Wolcott D, Carr CR, Harper R, Schweitzer SV, Nissenson AR: rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 39:155-163, 1991
6. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475, 2002
7. Schaefer RM, Leschke M, Strauer BE, Heidland A: Blood rheology and hypertension in hemodialysis patients treated with erythropoietin. Am J Nephrol 8:449-453, 1988
8. Raine AE, Roger SD: Effects of erythropoietin on blood pressure. Am J Kidney Dis 18:76-83, 1991
9. Abraham PA, Macres MG: Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol 2:927-936, 1991
10. Lebel M, Kingma I, Grose JH, Langlois S: Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients. J Am Soc Nephrol 9:97-104, 1998
11. Mayer G, Horl WH: Cardiovascular effects of increasing hemoglobin in chronic renal failure. Am J Nephrol 16:263-267, 1996
12. Steffen HM, Brunner R, Muller R, Degenhardt S, Pollok M, Lang R, Baldamus CA: Peripheral hemodynamics, blood viscosity, and the reninangiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin. Contrib Nephrol 76:292-298, 1989
13. Raine AE: Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet 1:97-100, 1988
14. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998
15. Kaupke CJ, Kim S, Vaziri ND: Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol 4:1874-1878, 1994
16. Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC: Endothelin release and shift in prostaglandin balance are involved in the modulation of vascular tone by recombinant erythropoietin. J Cardiovasc Pharmacol 20(suppl):S25-S28, 1992
17. Vaziri ND, Zhou XJ, Smith J, Oveisi F, Baldwin K, Purdy RE: In vivo and in vitro pressor effects of erythropoietin in rats. Am J Physiol 269:F838-F845, 1995
18. Hand MF, Haynes WG, Johnstone HA, Anderton JL, Webb DJ: Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 48:806-813, 1995
19. Ksiazek A, Zaluska WT, Ksiazek P: Effect of recombinant human erythropoietin on adrenergic activity in normotensive hemodialysis patients. Clin Nephrol 56:104-110, 2001
20. Brochu E, Lacasse S, Lariviere R, Kingma I, Grose JH, Lebel M: Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. J Am Soc Nephrol 10:1440-1446, 1999
21. Tojo A, Doumoto M, Oka K, Numabe A, Kimura K, Yagi S: Endothelin-mediated effect of erythropoietin on blood pressure and renal hemodynamics in hypertensive rats. Am J Physiol 270:R744-R748, 1996
22. Zhou XJ, Pandian D, Wang XQ, Vaziri ND: Erythropoietin-induced hypertension in rat is not mediated by alterations of plasma endothelin, vasopressin, or atrial natriuretic peptide levels. J Am Soc Nephrol 8:901-905, 1997
23. Miyashita K, Tojo A, Kimura K, Goto A, Omata M, Nishiyama K, Fujita T: Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients. Hypertens Res 27:79-84, 2004
24. Carlini R, Obialo CI, Rothstein M: Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertens 6:103-107, 1993
25. Wang XQ, Vaziri ND: Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 33:894-899, 1999
26. Scalera F, Kielstein JT, Martens-Lobenhoffer J, Postel SC, Tager M, Bode-Boger SM: Erythropoietin increases asymmetric dimethylarginine in endothelial cells. role of dimethylarginine dimethylaminohydrolase. J Am Soc Nephrol 16:892-898, 2005
27. del Castillo D, Raij L, Shultz PJ, Tolins JP: The pressor effect of recombinant human erythropoietin is not due to decreased activity of the endogenous nitric oxide system. Nephrol Dial Transplant 10:505-508, 1995
28. Vaziri ND, Zhou XJ, Naqvi F, Smith J, Oveisi F, Wang ZQ, Purdy RE: Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol 271:E113-E122, 1996
29. Vaziri ND: Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 33:821-828, 1999
30. Eggena P, Willsey P, Jamgotchian N, Truckenbrod L, Hu MS, Barrett JD, Eggena MP, Clegg K, Nakhoul F, Lee DB: Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol 261:E642-E646, 1991
31. Lai KN, Lui SF, Leung JC, Law E, Nicholls MG: Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis. Nephron 57:394-400, 1991
32. Kuriyama S, Tomonari H, Tokudome G, Kaguchi Y, Hayashi H, Kobayashi H, Horiguchi M, Ishikawa M, Hara Y, Hosoya T: Association of angiotensinogen gene polymorphism with erythropoietin-induced hypertension: a preliminary report. Hypertens Res 24:501-505, 2001
33. Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC: Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 50:1255-1261, 1996
34. Heidenreich S, Rahn KH, Zidek W: Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 39:259-265, 1991
35. Erne P, Bolli P, Burgisser E, Buhler FR: Correlation of platelet calcium with blood pressure. Effect of antihypertensive therapy. N Engl J Med 310:1084-1088, 1984
36. Neusser M, Tepel M, Zidek W: Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. Cardiovasc Res 27:1233-1236, 1993
37. 2+ channels: activation by phospholipase C-gamma 1. Kidney Int 53:1259-1268, 1998
38. Ammarguellat F, Gogusev J, Drueke TB: Direct effect of erythropoietin on rat vascular smooth-muscle cell via a putative erythropoietin receptor. Nephrol Dial Transplant 11:687-692, 1996
39. Akimoto T, Kusano E, Inaba T, Iimura O, Takahashi H, Ikeda H, Ito C, Ando Y, Ozawa K, Asano Y: Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int 58:269-282, 2000
40. Shiojima I, Walsh K: Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 90:1243-1250, 2002
41. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S, Rosenbaum PS, Cerami A, Brines M, Rosenbaum DM: Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA 99:10659-10664, 2002
42. Becerra SP, Amaral J: Erythropoietin - an endogenous retinal survival factor. N Engl J Med 347:1968-1970, 2002
43. Berman DH, Friedman EA: Partial absorption of hard exudates in patients with diabetic end-stage renal disease and severe anemia after treatment with erythropoietin. Retina 14:1-5, 1994
44. Friedman EA, L'Esperance FA, Brown CD, Berman DH: Treating azotemia-induced anemia with erythropoietin improves diabetic eye disease. Kidney Int Suppl 87:S57-S63, 2003
45. Carlini RG, Reyes AA, Rothstein M: Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 47:740-745, 1995
46. Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T, Murakami T, Kobayashi T, Masuda S, Nagao M, Yoshimura N, Takagi H: Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 353:782-792, 2005
47. Smith KJ, Bleyer AJ, Little WC, Sane DC: The cardiovascular effects of erythropoietin. Cardiovasc Res 59:538-548, 2003
48. Lee IG, Chae SL, Kim JC: Involvement of circulating endothelial progenitor cells and vasculogenic factors in the pathogenesis of diabetic retinopathy. Eye 20:546-552, 2006
49. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78, 1987
50. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, Korbet S, Krantz SB, Lundin AP, Nissenson AR, Ogden DA, Paganini EP, Rader B, Rutsky EA, Stivelman J, Stone WJ, Teschan P, Van Stone JC, Van Wyck DB, Zuckerman K, Adamson JW: Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111:992-1000, 1989
51. Edmunds ME, Walls J, Tucker B, Baker LR, Tomson CR, Ward M, Cunningham J, Moore R, Winearls CG: Seizures in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 4:1065-1069, 1989
52. Goodnough LT, Rudnick S, Price TH, Ballas SK, Collins ML, Crowley JP, Kosmin M, Kruskall MS, Lenes BA, Menitove JE, Silberstein LE, Smith KJ, Wallas CH, Abels R, Von Tress M: Increased preoperative collection of autologous blood with recombinant human erythropoietin therapy. N Engl J Med 321:1163-1168, 1989
53. Fischl M, Galpin JE, Levine JD, Groopman JE, Henry DH, Kennedy P, Miles S, Robbins W, Starrett B, Zalusky R et al.: Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 322:1488-1493, 1990
54. Viron B, Chamma F, Jaar B, Michel C, Mignon F: Thrombosis of angioaccess in haemodialysed patients treated with human recombinant erythropoietin. Nephrol Dial Transplant 12:368-370, 1997
55. Muirhead N, Laupacis A, Wong C: Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadian Erythropoietin Study Group). Nephrol Dial Transplant 7:811-816, 1992
56. Turitto VT, Weiss HJ: Red blood cells: their dual role in thrombus formation. Science 207:541-543, 1980
57. Tang WW, Stead RA, Goodkin DA: Effects of epoetin alfa on hemostasis in chronic renal failure. Am J Nephrol 18:263-273, 1998
58. Malyszko J, Malyszko JS, Borawski J, Rydzewski A, Kalinowski M, Azzadin A, Mysliwiec M, Buczko W: A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy. Thromb Res 77:133-143, 1995
59. Wirtz JJ, van Esser JW, Hamulyak K, Leunissen KM, van Hooff JP: The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients. Clin Nephrol 38:277-282, 1992
60. Bennett WM: A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease. J Am Soc Nephrol 1:990-998, 1991
61. De Marchi S, Cecchin E, Falleti E, Giacomello R, Stel G, Sepiacci G, Bortolotti N, Zanello F, Gonano F, Bartoli E: Long-temi effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients. J Am Soc Nephrol 8:1147-1156, 1997
62. Brines ML, Ghezzi P, Keenan S, de Agnello D, Lanerolle NC, Cerami C, Itri LM, Cerami A: Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97:10526-10531, 2000
63. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, Ruthe E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, Siren AL: Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8:495-505, 2002
64. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M: Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100:4802-4806, 2003
65. Erbayraktar S, Grasso G, Sfacteria A, Xie QW, Coleman T, Kreilgaard M, Torap L, Sager T, Erbayraktar Z, Gokmen N, Yilmaz O, Ghezzi P, Villa P, Fratelli M, Casagrande S, Leist M, Helboe L, Gerwein J, Christensen S, Geist MA, Pedersen LO, Cerami-Hand C, Wuerth JP, Cerami A, Brines M: Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 100:6741-6746, 2003
66. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, Savino C, Bianchi M, Nielsen J, Gerwien J, Kallunki P, Larsen AK, Helboe L, Christensen S, Pedersen LO, Nielsen M, Torup L, Sager T, Sfacteria A, Erbayraktar S, Erbayraktar Z, Gokmen N, Yilmaz O, Cerami-Hand C, Xie QW, Coleman T, Cerami A, Brines M: Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305:239-242, 2004
67. Babb AL, Popovich RP, Farrell PC, Blagg CR: The effects of erythrocyte mass transfer rates on solute clearance measurements during haemodialysis. Proc Eur Dial Transplant Assoc 9:303-321, 1972
68. Bennett WM: Side effects of erythropoietin therapy. Am J Kidney Dis 18:84-86, 1991
69. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2:1175-1178, 1986
70. Kaufman JS, Reda DJ, Eye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA: Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 339:578-583, 1998
71. Frenken LA, van Lier HJ, Jordans JG, Leunissen KM, van Leusen R, Verstappen VM, Koene RA: Identification of the component part in an epoetin alfa preparation that causes pain after subcutaneous injection. Am J Kidney Dis 22:553-556, 1993
72. Veys N, Vanholder R, Lameire N: Pain at the injection site of subcutaneously administered erythropoietin in maintenance hemodialysis patients: a comparison of two brands of erythropoietin. Am J Nephrol 12:68-72, 1992
73. St. Peter WL, Lewis MJ, Macres MG: Pain comparison after subcutaneous administration of single-dose formulation versus multidose formulation of epogen in hemodialysis patients. Am J Kidney Dis 32:470-474, 1998
74. Morris KP, Hughes C, Hardy SP, Matthews JN, Coulthard MG: Pain after subcutaneous injection of recombinant human erythropoietin: does EMLA cream help? Nephrol Dial Transplant 9:1299-1301, 1994